GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (NAS:RGEN) » Definitions » Accounts Receivable

Repligen (Repligen) Accounts Receivable : $124.2 Mil (As of Dec. 2023)


View and export this data going back to 1986. Start your Free Trial

What is Repligen Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Repligen's accounts receivables for the quarter that ended in Dec. 2023 was $124.2 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Repligen's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 72.75.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Repligen's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $1.66.


Repligen Accounts Receivable Historical Data

The historical data trend for Repligen's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Accounts Receivable Chart

Repligen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.07 71.39 117.42 116.25 124.16

Repligen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 116.25 133.49 120.30 106.16 124.16

Repligen Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Repligen Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Repligen's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=124.161/155.743*91
=72.75

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Repligen's accounts receivable are only considered to be worth 75% of book value:

Repligen's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(751.323+0.75 * 124.161+0.5 * 202.321-853.208
-0-0)/55.7661
=1.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Repligen Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Repligen's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Repligen (Repligen) Business Description

Traded in Other Exchanges
Address
41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
Executives
Christine Gebski officer: See Remarks C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. 1, SUITE 100, WALTHAM MA 02453
Olivier Loeillot officer: President and CCO C/O REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453
Jason K Garland officer: CFO 10000 WEHRLE DRIVE, CLARENCE NY 14031
Karen A Dawes director 579 BELLEVUE AVE, NEWPORT RI 02840
Martin D Madaus director 290 CONCORD ROAD, BILLERICA MA 01821
Jon Snodgres officer: CFO REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING #1, SUITE 100, WALTHAM MA 02435
Anthony Hunt director, officer: Chief Executive Officer 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Ralf Kuriyel officer: Senior VP, R&D 41 SEYON ST, BLDG 1, STE. 100, WALTHAM MA 02452
James Bylund officer: SVP, Global Operations & IT C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. SUITE 100, WALTHAM MA 02453
Konstantin Konstantinov director C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Manner Carrie Eglinton director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ryan Thomas F Jr director
Nicolas Barthelemy director 1750 BELLA LAGUNA CT, ENCINITAS CA 92024
John Cox director C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Rohin Mhatre director C/O REPLIGEN CORP., 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453

Repligen (Repligen) Headlines

From GuruFocus

Frank Sands' Top 3rd-Quarter Trades

By Margaret Moran 11-09-2022

Repligen Corporation to Present at Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 07-04-2022

Repligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-03-2023

Repligen Corporation to Present at Upcoming Investor Conferences

By sperokesalga sperokesalga 05-31-2023

Repligen Corporation to Present at Upcoming Investor Conferences

By Value_Insider Value_Insider 11-08-2022

Repligen Corporation to Present at Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 06-24-2022

Repligen to Report First Quarter 2023 Financial Results

By sperokesalga sperokesalga 04-18-2023